

## LISTA LUCRĂRILOR ȘTIINȚIFICE DE SPECIALITATE

### I. Teza de Doctorat

1. **Bălașa R.** *Studiul comparativ între aspectele potențialelor evocate și imaginile prin rezonanță magnetică în nevrita optică și scleroza multiplă.* Anul 2003, 355 pg.

Universitatea de Medicină și Farmacie Târgu Mureș, Facultatea de Medicină  
Calificativul obținut: „*Cum Laude*”.

### II. Cărți de specialitate

1. **Rodica Balasa**, Smaranda Maier, Laura Barcutean. *Scleroza Multipla.* University Press 2024. ISBN: 978-973-169-857-1.
2. Zoltan Bajko, **Rodica Bălașa**, Laura Bărcuțean, Adina Stoian, Smaranda Maier, Anca Motataianu, Sebastian Andone. *Curs de Neurologie pentru Medicina Dentară* University Press Târgu Mureș 2021, ISBN: 978-973-169-740-6
3. **Bălașa R**, Maier S, Moțățiaianu A, Bajkó Z, Bărcuțean L, Romaniuc A, Andone S. *Patologia neurologică-cazuri clinice.* Editura University Press Târgu Mureș, 2019, 1520 pg, ISBN 978-973-169-617-1.
4. **Bălașa R**, Moțățiaianu A, Bălașa A. *Curs de neurologie*, Vol I. Editura University Press Târgu Mureș, 2015, 280 pg, ISBN 978-973-169-452-1.
5. **Bălașa R**, Maier S, Moțățiaianu A, Bajkó Z, Bălașa A. *Curs de neuoreabilitare.* Editura University Press Târgu Mureș, 2014, 178 pg, ISBN 978-973-297-5.
6. **Bălașa A**, Chinezu R, **Bălașa R**, Chinezu L. *Curs de neurochirurgie.* Editura University Press Târgu Mureș, 2014, 143 pg, ISBN 978-973-169-313-2.
7. **Bălașa R.** *Major neurological syndromes.* Editura University Press Târgu Mureș, 2012, 252 pg, ISBN 978-973-169-191-6.
8. **Bălașa R.** *Nervii cranieni.* Editura University Press Târgu Mureș, 2010, 248 pg, ISBN 978-973-169-122-0.
9. Bălașa A, **Bălașa R.** *Tumorile spinale: clinică, imagistică, tratament chirurgical (DVD),* Editura University Press Târgu Mureș, 2008, ISBN 978-973-169-036-0.
10. **Bălașa R**, Pascu I. *Sindroame neurologice majore.* Editura University Press Târgu Mureș, 2006, 206 pg, ISBN 978-973-7665-34-8.
11. Pascu I, **Bălașa R.** *Neuropatia diabetică.* Editura University Press Târgu Mureș, 2006, 105 pg, ISBN 978-973-7665-08-9.
12. Pascu I, **Bălașa R.** *Scleroza multiplă.* Editura University Press Târgu Mureș, 1999, 163 pg, ISBN 973-98753-0-0.

### **III. Capitole de specialitate în volume colective**

1. **Bălașa R.** Bălașa A. Manifestări oftalmologice în come. În: Dumitrache M (Ed). Neurooftalmologie, Editura Academiei Române, București 2019, pag 529-541 ISBN: 978-973-27-3126-0
2. **Bălașa R.** Sindroame neurologice cu manifestări aculare. În: Dumitrache M (Ed). Neurooftalmologie, Editura Academiei Române, București 2019, pag 566-591 ISBN: 978-973-27-3126-0
3. **Bălașa R.** *Afectarea arterială a căilor vizuale la vârstnici.* În: Dumitrache M (Ed). Boli oculare la persoane în vârstă, Editura Medicală Callistro, București, 2018, pg 401-413, ISBN: 978-606-8043-34-0.
4. **Balasa R.** *Iatrogenic lesions in neurology.* In: Gurzu S, Jung I (Eds). Textbook of iatrogenic pathology, Bentham Science Publ, Sharjah, UAE, 2017, pg 210-230. ISBN (print): 978-1-68108-515-9.
5. **Bălașa R.** *Afecțiuni neurologice cu manifestări oculare.* În: Dumitrache M (Ed). Compendiu de patologie oftalmologică, Editura Medicală, București, 2015, pg 451-470, ISBN: 978-973-39-0795-4.
6. **Bălașa R.** *Sindroame neurologice cu manifestări oculare.* În: Dumitrache M (Ed). Sindroame și boli sistemice cu manifestări oculare, Editura Medicală, București, 2014, pg 413-443, ISBN 978-973-39-0769-5.
7. **Bălașa R.** *Nevrita optică și scleroza multiplă.* În: Dumitrache M (Ed). Neurooftalmologie, Editura Universitară Carol Davila, București, 2013, pg 351-376, ISBN 978-973-708-629-7.
8. **Bălașa R,** Pascu I. *Atacurile cerebrovasculare.* În: Chioreanu M, Copotoiu SM, Azamfîrei L (Eds). Managementul bolnavului critic, vol III, Editura University Press, Târgu Mureș, 2006, pg 33-65, ISBN 973-7788-78-8.
9. **Bălașa R,** Pascu R, Pascu I. *Infecțiile intracraniene.* În: Chioreanu M, Copotoiu SM, Azamfîrei L (Eds). Managementul bolnavului critic, vol III, Editura University Press, Târgu Mureș, 2006, pg 67-94, ISBN 973-7788-78-8.

#### **IV. Lucrări științifice de specialitate publicate în extenso în reviste indexate ISI**

1. Farczadi L, Barcutean L, Maier S, **Balasa R**, Imre S. Development and Validation of a New LC-MS/MS Method for the Assay of Plasmatic Peripheral Short- and Medium-Chain Fatty Acids for Metabolomics Applications. *Metabolites*. 2025 Jun 16;15(6):403. IF: 3.7. Q2
2. Andone S, Lénárd F, Imre S, Dumitreasa M, **Bălașa R**. Fatty Acid Ratios Versus Conventional Risk Factors in Stroke: Insights into Severe Disability and Mortality Outcomes. *Nutrients*. 2025 Apr 30;17(9):1518. IF: 5.0. Q1
3. Moțățianu A, Mănescu IB, Șerban G, Ion V, **Bălașa R**, Andone S. The Effects of a Mediterranean Diet on Metabolic Hormones and Cytokines in Amyotrophic Lateral Sclerosis Patients: A Prospective Interventional Study. *Nutrients*. 2025 Apr 25;17(9):1437. IF: 5.0. Q1
4. Mosora O, Maier S, Manu D, Bărcuțean L, Roman M, Dumitreasă M, **Bălașa R**. Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis. *Int J Mol Sci*. 2025 Apr 20;26(8):3889. IF: 4.9. Q1
5. Manu DR, **Bălașa R**, Pruteanu LL, Curean V, Barbu-Tudoran L, Șerban GM, Chinezu R, Bălașa A. Identification of distinct profiles of glioblastoma through the immunocapture of extracellular vesicles from patient plasma. *PLoS One*. 2025 Mar 19;20(3):e0315890. IF: 2.6. Q2
6. Șerban GM, Manu D, **Balasa R**, Balasa AF. Extracellular Vesicle-Based Characterization of Stem Cell Phenotype in Glioblastomas. *Cureus*. 2024;28:16(9):ee70403. IF: 1.3.
7. Forró T, Manu DR, Barbu-Tudoran L, **Bălașa R**. Astrocyte Dysfunction Reflected in Ischemia-Induced Astrocyte-Derived Extracellular Vesicles: A Pilot Study on Acute Ischemic Stroke Patients. *Int J Mol Sci*. 2024 Nov 20;25(22):12471. IF: 4.9. Citations 1. Q1
8. Maier S, Hutanu A, Barcutean L, Sarlasan E, **Balasa R**. Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients. *RRML* 2024;3. IF:0.5. Q4
9. Schenk A, Popa CO, Cojocaru CM, Marian Ș, Maier S, Băjenaru OL, **Bălașa R**. An Online Single-Session Cognitive Behavioral Therapy for Depression and Anxiety Associated with Multiple Sclerosis-Pilot Study. *Behav Sci (Basel)*. 2024 Jul 21;14(7):620. IF: 2.5. Q2
10. Schenk A, Popa CO, Cojocaru CM, Marian Ș, Maier S, **Bălașa R**. The Path from Personality to Anxiety and Depression Is Mediated by Cognition in Multiple Sclerosis. *J Pers Med*. 2024 Jun 25;14(7):682. IF: 3. Q2
11. Forró T, Manu DR, Băjenaru OL, **Bălașa R**. GFAP as Astrocyte-Derived Extracellular Vesicle Cargo in Acute Ischemic Stroke Patients-A Pilot Study. *Int J Mol Sci*. 2024 May 24;25(11):5726. IF: 4.9. Citations 1. Q1
12. Moțățianu A, Mănescu IB, Șerban G, Bărcuțean L, Ion V, **Bălașa R**, Andone S. Exploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis. *Int J Mol Sci*. 2024 May 7;25(10):5059. IF: 4.9. Q1
13. Moțățianu A, Andone S, Stoian A, **Bălașa R**, Huțanu A, Sărmășan E. A Potential Role of Interleukin-5 in the Pathogenesis and Progression of Amyotrophic Lateral Sclerosis: A New Molecular Perspective. *Int J Mol Sci*. 2024 Mar 28;25(7):3782. IF: 4.9. Q1
14. Stoian A, Bajko Z, **Bălașa R**, Andone S, Stoian M, Ormenișan I, Muntean C, Bănescu C. Characteristics of Developmental and Epileptic Encephalopathy

- Associated with PACS2 p.Glu209Lys Pathogenic Variant-Our Experience and Systematic Review of the Literature. *Biomolecules*. 2024 Feb 23;14(3):270. IF: 4.8. Citations 1. Q1
15. Barcutean L, Farczadi L, Manescu IB, Imre S, Maier S, **Balasa R**. Short and Medium Chain Fatty Acids in a Cohort of Naïve Multiple Sclerosis Patients: Pre- and Post-Interferon Beta Treatment Assessment. *Biologics*. 2024 Nov 15;18:349-361. IF:5.3. Q1
  16. Barcutean L, Maier S, Burai-Patrascu M, Farczadi L, **Balasa R**. The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis. *Int J Mol Sci*. 2024 Mar 11;25(6):3198. IF: 5.6. Citations 8. Q1
  17. Barcutean L, Maier S, Bajko Z, Stoian A, Mosora O, Sarmasan E, Manescu IB, **Balasa R**. Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression. *J Clin Med*. 2024 Mar 21;13(6):1813. IF: 3.9. Citations 1. Q2
  18. Parau D, Todoran AB, **Balasa R**. Physiotherapy Intervention on Premature Infants-A Pilot Study. *Medicina (Kaunas)*. 2024 Jan 11;60(1):138. IF: 2.94. Q1
  19. Parau D, Todoran AB, **Balasa R**. Factors Influencing the Duration of Rehabilitation in Infants with Torticollis-A Pilot Study. *Medicina (Kaunas)*. 2024 Jan 16;60(1):165. IF. 2.94. Q1
  20. Manu DR, Slevin M, Barcutean L, Forro T, Boghitoiu T, **Balasa R**. Astrocyte Involvement in Blood-Brain Barrier Function: A Critical Update Highlighting Novel, Complex, Neurovascular Interactions. *Int J Mol Sci*. 2023 Dec 5;24(24):17146. IF. 6.20. Citations 22. Q1
  21. Roman Filip I, Morosanu V, Spinu D, Motoc C, Bajko Z, Sarmasan E, Roman C, **Balasa R**. Cervical Artery Dissections-A Demographical Analysis of Risk Factors, Clinical Characteristics Treatment Procedures, and Outcomes-A Single Centre Study of 54 Consecutive Cases. *J Pers Med*. 2023 Dec 29;14(1):48. IF: 3.50. Q1
  22. Maier S, Bajkó Z, Roşescu R, Bărcuţean L, Sărmăşan E, Voidăzan S, **Bălaşa R**. Sociodemographic and Clinical Determinants of Fatigue in Multiple Sclerosis. *Life (Basel)*. 2023 Oct 29;13(11):2132. IF. 3.25. Citations 4. Q1
  23. Parau D, Todoran AB, Barcutean L, Avram C, **Balasa R**. The Benefits of Combining Bobath and Vojta Therapies in Infants with Motor Development Impairment-A Pilot Study. *Medicina (Kaunas)*. 2023 Oct 23;59(10):1883. doi: 10.3390/medicina59101883. IF: 2.6. Citations 3. Q1
  24. Morosanu V, **Balasa R**, Morosanu S, Baróti B, Roman-Filip I. Delayed Demyelinating Disease of the Central Nervous System Following Low-Voltage Alternating Current Electrical Injury: A Case Report and Review of the Literature. *Cureus*. 2023 Aug 22;15(8):e43951. IF. 1.2. ESCI
  25. Barcutean L, Hutanu A, Andone S, Maier S, **Balasa R**. The peripheral profile of the chitinase 3-like-1 in benign multiple sclerosis - a single centre's experience. *CNS Neurol Disord Drug Targets*. 2023 Jun 9. IF. 3.0. Q3
  26. Stoian A, Bajko Z, Stoian M, Cioflinc RA, Niculescu R, Arbănaşi EM, Russu E, Botoncea M, **Bălaşa R**. The Occurrence of Acute Disseminated Encephalomyelitis in SARS-CoV-2 Infection/Vaccination: Our Experience and a Systematic Review of the Literature. *Vaccines (Basel)*. 2023 Jul 10;11(7):1225. IF: 7.8. Citations 11. Q1
  27. Roman-Filip I, Morosanu V, Bajko Z, Roman-Filip C, **Balasa R**. Non-Aneurysmal Perimesencephalic Subarachnoid Hemorrhage: A Literature Review. *Diagnostics*. 2023; 13:1195. IF: 3.6. Citations 3. Q1

28. Maier S, Barcutean L, Andone S, Manu D, Sarmasan E, Bajko Z, **Balasa R**. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. *IJMS*. 2023;24:4375. IF: 5.6. Citations 5. Q1
29. Andone S, Farczadi L, Imre S, Bajko S, Motataianu A, Maier S, Barcutean L, **Balasa R**. Serum Fatty Acids Are Associated with a Higher Risk of Ischemic Stroke. *Nutrients*. 2023; 15:585. IF: 5.9. Citations 1. Q1
30. Serban G, Tamas F, **Balasa R**, Manu D, Tamas C, Balasa A. Prognostic Factors of Survival in Glioblastoma Multiforme Patients-A Retrospective Study. *Diagnostics*. 2022;12:2630. IF: 3.6. Citations 4. Q2
31. Andone S, Farczádi L, Imre S, **Bălașa R**. Fatty Acids and Lipid Paradox-Neuroprotective Biomarkers in Ischemic Stroke. *Int J Mol Sci*. 2022 Sep 16;23(18):10810. IF: 5.6. Citations 7. Q1
32. **Balasa R**, Maier S, Hutanu A, Voidazan S, Andone S, Oiaga M, Manu D. Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients. *IJMS*. 23:10262. IF: 5.6. Citations 1. Q1
33. Motataianu A, Serban G, Barcutean L, **Balasa R**. Oxidative Stress in Amyotrophic Lateral Sclerosis: Synergy of Genetic and Environmental Factors. *IJMS*. 2022;23:9339. IF: 5.6. Citations 29. Q1
34. Andone S, Bajko Z, Motataianu A, Maier S, Barcutean L, **Balasa R**. Neuroprotection in Stroke – Focus on the renin-angiotensin system: a systematic review. *IJMS*. 2022;23:3876. IF: 6.208. Citations 8. Q1
35. Stoian A, Stoian M, Bajko Z, Maier S, Andone S, Cioflinc RA, Motataianu A, Barcutean L, **Balasa R**. Autoimmune encephalitis in COVID-19 infection: Our experience and systematic review of the literature. *Biomedicines*. 2022;25:774. IF 4.75. Citations 24. Q1
36. Bajko Z, Maier S, Motataianu A, Filep RC, Stoian A, Andone S, **Balasa R**. Rivaroxaban for the treatment of cerebral venous thrombosis: a single-center experience. *Acta Neurol Belgica*. 2021; ahead of print. DOI: 10.1007/s13760-021-01651-z. FI: 1.98. Citations: 7. Q3
37. Tamas F, **Balasa R**, Manu D, Gyorki G, Chinezu R, Tamas C, Balasa A. The importance of small extracellular vesicles in the cerebral metastatic process. *IJMS*. 2022;23:1449. IF: 6.20. Citations 9. Q1
38. Tiu C, Teracoasa EO, Tuta S, **Balasa R**, Simu M, Sabau M, Stan A, Radu RA, Tiu V, Casaru B, Negrila A, Panea C. Quality of acute stroke care in Romania: Achievements and gaps between 2017 and 2022. *European Stroke Journal*. 2022;1-8. IF: 5.89. Citations 8. Q1
39. Dobreanu M, Manu DR, Manescu IB, Gabor MR, Hutanu A, Barcutean L, **Balasa R**. Treatment With Cladribine Selects IFN $\gamma$ +IL17+ T Cells in RRMS Patients - An In Vitro Study. *Front Immunol*. 2021;12:743010. IF: 8.78. Citations 2. Q1
40. Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, Draghici IA, Cioban A, **Balasa R**. Prevalence and clinical characteristics of subclavian steal phenomenon/syndrome in patients with acute ischemic stroke. *J Clin Med*. 2021;10:5237. IF: 4.24. Citations 6. Q1
41. Motataianu A, Barcutean L, Bajko Z, Stoian A, Maier S, Voidazan S, **Balasa R**. Autonomic and Somatic Nerve functions in type 2 diabetes mellitus patients: electrophysiological aspects. *Diagnostics*. 2021;11:2005. IF: 3.70. Citations 5. Q1
42. Stoian A, **Balasa R**, Grigorescu BL, Maier S, Andone S, Cocuz IG, Bajko Z, Filep CR, Stoian M. Guillain-Barré syndrome associated with Covid-19: A close

- relationship or just a coincidence? (Review). *Exp Ther Med*. 2021;22:916. IF:2.44. Citations 8. Q3
43. **Balasa R**, Barcutean L, Mosora O, Manu D. Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. *Int J Mol Sci*. 2021;22:8370. IF: 5.92. Citations 76. Q1
  44. Andone S, Bajko Z, Motataianu A, Mosora O, **Balasa R**. The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review. *Int J Mol Sci*. 2021;22:9032. FI: 5.92. Citations 11. Q1
  45. Bajko Z, **Balasa R**, Maier S, Motataianu A, Barcutean L, Andone S, Stoian A, Filep RC. Stroke secondary to giant-cell arteritis: A literature review. *Exp Ther Med*. 2021 Aug;22(2):876. IF 2.4. Citations 17. Q4
  46. Stoian A, Bajko Z, Maier S, Cioflinc RA, Grigorescu BL, Motataianu A, Barcutean L, **Balasa R**, Stoian M. High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). 2021;1182. IF: 1.78. Citations 13. Q4
  47. Mosora O, Barcutean L, **Balasa R**, Fodor R, Maier S, Bajko Z, Stoian A, Motataianu A. Severe Acute Motor Axonal Neuropathy associated with Influenza-A (H1N1) Infection and Prolonged Respiratory Failure - A Case Report. *J Crit Care Med (Targu Mures)*. 2021 Nov 6;7(4):302-307. ESCI
  48. Forró T, Bajko Z, Balasa A, **Balasa R**. Dysfunction of the Neurovascular Unit in Ischemic Stroke: Highlights on microRNAs and Exosomes as Potential Biomarkers and Therapy. *Int J Mol Sci*. 2021;22:5261. FI: 4.55. Citations: 30. Q1
  49. Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone Sebastian, Maier S, Draghici IA, Cioban A, **Balasa R**. Gender Differences in Risk Factor Profile and Clinical Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis. *J Clin Med*. 2021;30;1382. DOI: 10.3390/jcm10071382. FI: 3.30. Citations: 10. Q1
  50. Bajko Z, Motataianu A, Stoian A, Barcutean L, Andone S, Maier S, Draghici IA, **Balasa R**. Postpartum cerebral venous thrombosis – a single center experience. *Brain Sciences*. 2021;11:1-9. DOI: 10.3390/brainsci11030327. FI: 3.33. Citations: 7. Q3
  51. Maier S, Simu M, Hutanu A, Barcutean L, Voidazan S, Bajko Z, Motataianu A, Lata I, **Balasa R**. Clinical immunological correlations in patients with multiple sclerosis treated with natalizumab. *Brain sciences*. 2020;10:1-11. DOI: 10.3390/brainsci10110802. FI: 3.33. Citations 2. Q3
  52. **Balasa R**, Barcutean L, Balasa A, Motataianu A, Roman-Filip C, Manu D. The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. *Human Immunology*. 2020;81:273-243. DOI: 10.1016/j.humimm.2020.02.009. FI: 2.41. Citations: 61. Q3
  53. Stoian A, Motataianu A, Barcutean L, Maier S, Bajko Z, Voidazan S, Farcas A, **Balasa R**. Understanding the mechanism of action of intravenous Immunoglobulins: a ten years' experience in treating Guillain barré syndrome. *Farmacia*. 2020;68:426-435. FI: 1.60. Citations: 10. Q4
  54. Romaniuc A, **Bălașa R**, Știrbu N, Maier S, Andone S, Bajko Z, Bărcuțean L, Voidăzan S, Moțățăianu A. The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients. *Behavioural Neurology*. 2020, Article ID 2594702, DOI: 10.1155/2020/2594702. FI: 1.90. Citations 5. Q2
  55. **Balasa R**. Therapeutic Plasma Exchange: An Indispensable Therapy for Severe Neurological Condition. *J Crit Care Med (Targu Mures)*. 2020 May 6;6(2):89-90. ESCI

56. Moțățianu A, Bărcuțean L, **Bălașa R**. Neuroimmunity in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2020, 0: 1-8. DOI: 10.1080/21678421.2019.1708949. FI: 2.88. Citations: 11. Q2
57. Hutanu A, Iancu M, Maier S, **Balasa R**, Dobreanu M. Plasma biomarkers as potential predictors of functional dependence in daily life activities after ischemic stroke: A single center study. *Ann Ind Acad Neurol*. 2020;23:496-503. Doi:10.4103/aian.AIAN\_74\_19. FI: 0.89. Citations: 2. Q4
58. **Bălașa R**, Maier S, Bărcuțean L, Stoian A, Moțățianu A. The direct deleterious effect of Th17 cells in the nervous system compartment in multiple sclerosis and experimental autoimmune encephalomyelitis: one possible link between neuroinflammation and neurodegeneration. *Revista Română de Medicină de Laborator* 2020, 28 (1), DOI:10.2478/rrlm-2020-0005. FI: 0.80. Citations: 1. Q4
59. Maier S, Moțățianu A, Bărcuțean L, Balint A, Huțanu A, Bajko Z, Stoian A, Romaniuc A, Andone S, **Bălașa R**. Interferon- $\beta$  1a, an immunomodulator in relapsing remitting multiple sclerosis patients. The effect on pro-inflammatory cytokines. *Farmacia* 2020, 68 (1). DOI:10.31925/farmacia.2020.1.10, FI: 1.52. Citations: 2. Q4
60. Bajkó Z, Andone S, Buruian M, Filep R, **Bălașa R**. Unilateral deep cerebral venous sinus thrombosis with reversible secondary parkinsonism. *Acta Neurol Belgica*. Epub 2018. 2020;120:503-506. DOI: 10.1007/s13760-018-0982-0. FI: 1.61. Citations: 2. Q3
61. Hutanu A, Iancu M, Dobreanu M, Oprea OR, Barbu S, Maier S, Tero-Vescan A, Bajko Z, **Balasa R**. Extended lipid profile in Romanian ischemic stroke patients in relation to stroke severity and outcome:a path analysis model. *Arch Med Sci* 2019; <https://doi.org/10.5114/aoms.2019.89302>. FI: 2.28.
62. Bajko Z, Filep RC, Maier S, Motataianu A, Andone S, **Balasa R**. Bilateral vertebral artery without stroke secondary to giant cell arteritis. *Acta Reumatol Port* 2019; 44:155-157. FI: 0.77.
63. Maier S, Copotoiu M, Romaniuc A, Andone S, **Bălașa R**. Central-variant reversible encephalopathy syndrome in a young patient with systemic lupus erythematosus. *Acta Neurol Belgica* 2019; 119: 269-271. FI: 1.61. Q3
64. Bărcuțean LI, Romaniuc A, Maier S, Bajkó Z, Moțățianu A, Huțanu A, Simu I, Andone S, **Bălașa R**. Clinical and serological biomarkers of treatment's response in patients treated continuously with interferon $\beta$ -1b for more than a decade. *CNS Neurol Disord Drug-Targets* 2018; 17: 720-792. FI: 2.08. Citations: 14. Q4
65. Moțățianu A, Maier S, Bajkó Z, Voidazan S, **Bălașa R**, Stoian A. Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. *BMC Neurology* 2018; 18: 126. Doi: 10.1186/s12883-018-1125-1. FI: 2.48. Citations:12.
66. Bajkó Z, Maier S, Moțățianu A, **Bălașa R**, Vasiu S, Stoian A, Andone S. Stroke Secondary to Traumatic Carotid Artery Injury - A Case Report. *J Crit Care Med (Targu Mures)*. 2018 Feb 9;4(1):23-28. ESCI
67. **Bălașa R**, Ciorba B, Voidazan S, Simu I, Huțanu A, Andone S, Romaniuc A, Moțățianu A, Maier S. The matrix metalloproteinases panel in multiple sclerosis patients treated with Natalizumab: A possible answer to Natalizumab non-responders. *CNS Neurol Disord Drug-Targets* 2018; 17: 464-472. FI: 2.08. Citations: 10. Q4
68. Huțanu A, Iancu M, **Bălașa R**, Maier S, Dobreanu M. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array. *Acta Pharmacol Sin* 2018; 39: 1228-1236. FI: 0.99. Citations:13.

69. Huțanu A, Maier M, **Bălașa R**, Oprea OR, Barbu Ș, Voidăzan S, Dobreanu M. Plasma phosphorylated neurofilament heavy chains as a potential marker for ischemic stroke patients. *Rom J Lab Med* 2018; 26: 59-64. DOI: <https://doi.org/10.2478/rllm-2018-0004>. FI: 0.32. Citations: 2. Q4
70. **Bălașa R**, Simu M, Voidăzan S, Bărcuțean LI, Bajko Z, Huțanu A, Simu I, Maier S. Natalizumab changes the peripheral profile of the Th17 panel in MS patients: New mechanisms of action. *CNS Neurol Disord Drug-Targets* 2017; 16: ISSN: 1018-1026. FI: 2.18. Citations: 23. Q4
71. Maier S, **Bălașa R**, Bajkó Z, Simu I, Horvath E. Complete progressive ophthalmoplegia and numb chin syndrome, the first clinical manifestations of a lethal abdominal Burkitt lymphoma. *Neurol Neurochir Polska* 2017; 51: 510-513. FI: 0.85. Citations: 3.
72. Gál R, **Bălașa R**, Bajkó Z, Maier S, Simu I, Bălașa A. Lethal Subarachnoid and Intracerebral Haemorrhage Associated with Temporal Arteritis. A Case Report. *J Crit Care Med (Targu Mures)*. 2017 Nov 8;3(4):153-157. ESCI
73. **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățianu A, Țilea B, Tiu C. Assessment of interleukin-17A, interleukin-10 and transforming growth factor-beta 1 serum titers in relapsing remitting multiple sclerosis patients treated with Avonex, possible biomarkers for treatment response. *CNS Neurol Disord Drug- Targets* 2017; 16: 93-101. FI: 2.18. Citations: 18. Q4
74. Țilea B, Voidăzan S, **Bălașa R**, Huțanu A, Fodor A. CXCL13 levels are more increased in cerebrospinal fluid and plasma of patients with acute infectious than in non-infectious diseases of central nervous system. *Rom J Lab Med* 2017; 25: DOI:10.1515/rllm-2016-0043. FI: 0.32. Citations: 1. Q4
75. **Bălașa R**. The Eleventh Hour: Neurosyphilis, Still Fashionable but a Controversial Diagnosis. *J Crit Care Med (Targu Mures)*. 2017 May 11;3(2):53-54. ESCI
76. Bajkó Z, Maier S, Moțățianu A, Stoian A, Bărcuțean L, **Bălașa R**. Repetitive Transient Ischaemic Attacks Secondary to a Floating Carotid Artery Thrombus in a Young Patient with Essential Thrombocythemia. *Journal of Cardiovascular Emergencies*. 2016;2:188-191. ESCI
77. Mărginean A, Bălănescu C, Moldovan V, Scridon A, Mărginean M, **Bălașa R**, Maier S, Țăruși M, Dobreanu M. The impact of CY2C19 polymorphism, clinical and demographic variables on platelet response to clopidogrel evaluated using impedance aggregometry. *Clin Appl Thromb/Hemost* 2017; 23: 255-265. FI: 2.39. Citations: 17.
78. Maier S, Bajkó Z, Moțățianu A, Rusu S, **Bălașa R**. Giant internal carotid artery aneurysm causing Collet-Sicard syndrome. *Acta Neurol Belgica* 2017; 117: 295-297. FI: 0.89. Citations: 3. Q3
79. Bălașa A, **Bălașa R**, Egyed-Zsigmond I, Chinezu R. Bilateral thalamic glioma: case report and review of the literature. *Turk Neurosurg* 2016; 26: 321-324. FI: 0.57. Citations: 5.
80. Bajkó Z, **Bălașa R**, Moțățianu A, Bărcuțean L, Stoian A, Stirbu N, Maier S. Malignant Middle Cerebral Artery Infarction Secondary to Traumatic Bilateral Internal Carotid Artery Dissection. A Case Report. *J Crit Care Med (Targu Mures)*. 2016 Aug 10;2(3):135-141. ESCI
81. **Bălașa R**, Maier S, Voidăzan S, Huțanu A, Bajkó Z, Moțățianu A. An intricate mechanism of action of Avonex in relapsing remitting multiple sclerosis patients: variation of serum titre of interleukin-17A, interleukin-10 and transforming growth factor-beta. *CNS Neurol Disord Drug Targets* 2015; 14: 804-810. FI: 2.70. Citations: 7. Q4

82. **Bălașa R**, Maier S, Bajkó Z, Pașcanu I, Moțățaiianu A. Skeletal muscle Na<sup>+</sup>/K<sup>+</sup>-ATPase pump dysfunction in thyrotoxic periodic paralysis: case report. *Acta Endocrinol (Buc)* 2015; 11: 240-245. FI: 0.21. Citations: 2.
83. **Bălașa R**, Maier S, Bajkó Z, Moțățaiianu A, Crișan A, Bălașa A. Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review. *Acta Neurol Belgica* 2015; 115: 635-642. FI: 0.598. Citations: 4. Q4
84. Maier S, Buruiian M, Maier A, Moțățaiianu A, Voidăzan S, Bajkó Z, **Bălașa R**. The determinants of depression in a Romanian cohort of multiple sclerosis patients. *Acta Neurol Belgica* 2015; DOI: 10.1007/s13760-015-0547-4. FI: 0.59. Citations: 8. Q4
85. Bajkó Z, **Bălașa R**, Szatmári S, Rusu S, Moțățaiianu A, Maier S. The role of ultrasound in the diagnosis of temporal arteritis. *Neurol Neurochir Polska* 2015; 49: 139-143. FI: 0.64. Citations: 2.
86. Stoian A, Bănescu C, **Bălașa R**, Moțățaiianu A, Stoian M, Moldovan VG, Voidăzan S, Dobreanu M. Influence of GSTM1, and GSTP1 polymorphisms on type 2 diabetes mellitus and diabetic sensorimotor peripheral neuropathy risk. *Dis Markers* 2015; ID 638693. FI: 1.56. Citations: 23.
87. Jung I, Gurzu S, **Bălașa R**, Moțățaiianu A, Contac AO, Halmaciu I, Popescu S, Simu I. A coin-like peripheral small lung carcinoma associated with acute paraneoplastic axonal Guillain-Barré-like syndrome. *Medicine (Baltimore)* 2015; 94: e910. FI: 4.25. Citations:12. Q2
88. **Bălașa R**, Maier S, Gliga Baubec E, Bajkó Z, Bălașa A. Cerebellar and brainstem variant of posterior reversible encephalopathy syndrome. *Acta Neurol Belg* 2015; 115: 401-403. FI: 0.59. Citations:1. Q4
89. **Bălașa R**, Bajkó Z, Moțățaiianu A, Maier A, Maier S. Neuromyelitis optica associated with painful dystonia: case report and literature review. *Acta Neurol Belg* 2015; 115: 169-171. FI: 0.59. Citations:1. Q4
90. **Bălașa R**, Maier S, Moțățaiianu A, Bajkó Z, Moldovan O, Benedek E. A case of fatal acute intermittent porphyria: laboratory diagnosis and pathogenesis considerations. *Rev Rom Med Lab* 2014; 22: 325-333. FI: 0.17. Citations:1. ESCI
91. Treabă AC, **Bălașa R**, Podoleanu DM, Simu IP, Buruiian MM. Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? *Diagn Interv Radiol* 2014; 20: 178-184. FI: 1.42. Citations: 9. Q4 SCIE
92. Moțățaiianu A, **Bălașa R**, Voidăzan S, Bajkó Z. Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus. *BioMed Res Internat* 2013, Article ID 507216. FI: 2.70. Citations:11. Q4
93. **Bălașa R**, Bajkó Z, Huțanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. *Mult Scler J* 2013; 19:885-890. FI: 4.863. Citations: 27. Q1
94. **Bălașa R**, Huțanu A, Bajkó Z, Feier C, Pascu I. Does the serum IL-17 titer influence the efficacy of interferon-beta treatment in multiple sclerosis? *Rom J Lab Med* 2011; 19: 381-389. IF: 0.091. Citations:10. ESCI
95. **Bălașa R**, Huțanu A, Feier C, Bajkó Z, Pascu I. Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon- $\beta$  treatment in multiple sclerosis patients. *Rom J Lab Med* 2010; 18: 39-50. IF: 0.113. Citations: 2. ESCI

**V. Lucrări științifice de specialitate publicate în extenso în reviste cotate ISI cu FI, articole colective**

- [1] Karelis G, Balasa R, De Bleecker J, Stuchevskaya T, Villa An, Van Damme P, Lagrange E, Heckmann JM, Nicolle M, Vilciu C, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubi S, Ayaguasanosa J. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. *Eur Neurol.* 2019;81(5-6):223-230. FI: 1.2. Citations: 6.
- [2] Kappos L, Bar-Or A, Bruce ACL, Fox RJ, Giovannoni G, Gold R, Vermersch P, Douglas LA, Arnould S, Scherz T, Wolf C, Wallstrom E, Dahlke F, Expand Clinical investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet.* 2018;391:1263-1273. **FI: 59.102.** [\[PubMed\]](#)
- [3] Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund-Singh S, Denison H, Ecans SR, Held P, Jahreskog M, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC, SOCRATES Steering Committee and Investigators. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). *Circulation.* 2017;136:907-916. **FI: 15.211.** [\[PubMed\]](#)
- [4] Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CAM, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Vignietta V, Dawson KT, CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. 2015;84:1145-1152. FI: 8.286. [\[PubMed\]](#)
- [5] Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffrey D, Kappos L, Montalban X, Boyko AN, Comi G, Allegro Study group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. *J Neurol Neurosurg Psychiatry.* 2014;85:851-858. **FI: 7.38.** [\[PubMed\]](#)

**VI. Lucrări științifice de specialitate publicate în extenso în reviste cotate CNCSIS B+ / ISI fara FL**

- [1] Serban G, **Balasa R**. SARS-CoV2 infection in a multiple sclerosis patient treated with natalizumab - A case presentation. *Acta Medica Marisiensis*. 2020;66:110-112.
- [2] Serban G, Balasa R. Review on multiple sclerosis management in times of SARS-CoV-2 pandemic. *Romanian Journal of Neurology*. 2020;19:70-75.
- [3] Bărcuțean LB, Maier S, Bajko Z, Moțățăianu A, Romaniuc A, Andone SR, **Bălașa R**. Interferon beta-1b for the treatment of multiple sclerosis – more than 10 years of experience. *Acta Medica Marisiensis* 2019; 65: 12-18.
- [4] Moțățăianu A, Maier S, Gothard A, Bajko Z, **Bălașa R**. Severe fatal systemic embolism due to non-bacterial thrombotic endocarditis as the initial manifestation of gastric adenocarcinoma: Case report. *J Crit Care Med* 2018; 4: 68-73.
- [5] Bajko Z, Andone S, Maier S, Moțățăianu A, Copotoiu M, Romaniuc A, Bărcuțean L, Stoian A, **Bălașa R**. Infarction of the posterior limb of internal capsule: The first clinical manifestation of lupus. *Rom J Neurol* 2018; 17: 168-171.
- [6] Andone S, Petruțiu S, Bajkó Z, Moțățăianu A, Maier S, Macavei I, Stoinan A, Bălașa A, **Bălașa R**. Sporadic Creutzfeldt-Jakob disease: a clinical approach of a small case series and literature review. *Rom J Neurol* 2017; 16: 109-115.
- [7] Maier S, Bajkó Z, Moțățăianu A, Stoian A, Șchiopu B, **Bălașa R**. Late Onset Tay-Sachs Disease in a Non-Jewish Patient: Case Report. *Acta Marisiensis-Seria Medica* 2017;63(4):199-203.
- [8] Stoian A, **Bălașa R**, Bărcuțean L, Moțățăianu A, Mocanu S. An unusual cause of longitudinally extensive transverse myelitis - case report. *Human & Veterinary Medicine* 2017;9:161-165.
- [9] **Bălașa R**. The eleventh hour: Neurosyphilis, still fashionable but a controversial diagnosis. *J Crit Care Med* 2017; 3; 53-55.
- [10] Maier S, Stirbu N, Bajkó Z, Moțățăianu A, Țilea B, Alexandrescu A, **Bălașa R**. Lyme meningoradiculitis: case reports and literature review. *Acta Medica Marisiensis* 2016; 62: 373-375.
- [11] Moțățăianu A, Bajkó Z, Maier S, Stoian A, Bărcuțean L, **Bălașa R**. Correlations between the severity of cardiovascular autonomic neuropathy and other complications in type 2 diabetes mellitus. *Rom J Neurol* 2016; 15: 16-23.
- [12] Țilea B, **Bălașa R**, Fodor A, Țilea I. Diagnosis and treatment algorithm in Lyme neuroborreliosis. *Acta Medica Marisiensis* 2016; 62: 121-127.
- [13] Stoian A, Moțățăianu A, Bajkó Z, Maier Z, Bărcuțean L, Stoian M, **Bălașa R**. Cardiovascular and renal prognosis in patients with arterial hypertension, type 2 diabetes mellitus and microalbuminuria. *HVM Bioflux* 2016; 8: 45-49.
- [14] **Bălașa R**. Nanoneurology. *Rom J Neurol* 2015; 14: 189-204.
- [15] Molnar K, **Bălașa R**. Effect of serum 25(OH) D level, cigarette smoking and oral contraceptive use on clinical course of relapsing-remitting multiple sclerosis in a group of female patients. *Rom J Neurol* 2015; 14: 214-218.
- [16] **Bălașa R**, Bajkó Z, Maier S, Voidăzan S, Moțățăianu A. Influence of risk factors and diabetic complications on peripheral nerve function in type 2 diabetes mellitus. *Acta Medica Marisiensis* 2015; 61: 25-31.
- [17] Maier S, **Bălașa R**, Bajkó Z, Maier A, Șchiopu B, Buruian M. Correlation between depression, cognitive status, functional scores, disability and lesion load in multiple sclerosis treated with interferon beta 1a. *Acta Medica Marisiensis* 2015; 61: 32-37.

- [18] Maier S, **Bălașa R**, Buruian M, Maier A, Bajkó Z. Depression in multiple sclerosis. *Rom J Neurol* 2015; 14: 22-29.
- [19] **Bălașa R**, Doboczi M, Costache O, Maier S, Bajkó Z, Moțățianu A, Bălașa A. Risk factors and diagnosis of cerebral venous thrombosis: data from a cohort of 45 Romanian patients. *Acta Medica Marisiensis* 2014; 60: 207-214.
- [20] **Bălașa R**, Bajkó Z, Maier Z, Moțățianu A. The dual role of transforming growth factor beta in the pathogenesis of multiple sclerosis and experimental encephalomyelitis. *Rom J Neurol* 2014; 13: 103-107.
- [21] **Bălașa R**, Huțanu A, Maier S. Serum interleukin-10 levels in multiple sclerosis patients treated with IFN- $\beta$  1A. *Acta Medica Transilvanica* 2014; 2: 193-196.
- [22] Băjenaru O, Antochi F, **Bălașa R**, Buraga I, Patrichi S, Simu M, Szatmári S, Tiu C, Zaharia C, et VTE-NEURO study group. Assessment of venous thrombolism prophylaxis in neurological patients with restricted mobility – VTE-NEURO study. *Mædica J Clin Med (Buc)* 2014; 9: 6-14.
- [23] **Bălașa R**, Bajkó Z, Moțățianu A, Maier S. Pitfalls in the diagnosis of neurosyphilis – case report and literature review. *Acta Medica Transilvanica* 2014; 2: 201-203.
- [24] Maier S, Bajkó Z, Moțățianu A, Maier A, Raicea V, Bardas A, **Bălașa R**. Subclavian double steal syndrome presenting with cognitive impairment and dizziness. *Rom J Neurol* 2014; 13: 144-149.
- [25] **Bălașa R**, Bajkó Z, Bălașa A, Mocan S, Chebuț O. An unusual case of seronegative Wegener's granulomatosis: acute pancreatitis at onset, followed by atrio-ventricular block, neurological and kidney involvement. *Rom J Neurol* 2013; 12: 43-46.
- [26] Bajkó Z, **Bălașa R**, Maier S, Moțățianu A, Treabă A, Macarie I, Gârbovan C, Chiriac C. *Listeria Monocytogenes* meningoencephalitis mimicking stroke in a patient with chronic lymphocytic leukemia. *Neurol & Ther* 2013; 2: 63-70.
- [27] Bajkó Z, **Bălașa R**, Moțățianu A, Maier S, Chebuț OC, Szatmári S. Common carotid artery occlusion: a case series. *ISRN Neurol* 2013, Article ID 198595.
- [28] Moțățianu A, Bajkó Z, Stoian A, **Bălașa R**. Cardiovascular autonomic neuropathy and sensorimotor polyneuropathy in type 2 diabetes mellitus. *Acta Medica Marisiensis* 2012; 58: 243-247.
- [29] **Bălașa R**, Bajkó Z, Stan C. Extracranial jugular venous insufficiency in multiple sclerosis patients treated with interferon beta. *Acta Medica Marisiensis* 2011; 57: 566-570.
- [30] Bajkó Z, **Bălașa R**, Stan C, Moțățianu A. Dissection of the cervicocerebral arteries – ultrasonic characteristics. *Acta Medica Marisiensis* 2011; 57: 413-417.
- [31] **Bălașa R**, Bajkó Z. Trigeminal neuralgia in multiple sclerosis: a clinical comparison of trigeminal neuralgia in patients with and without underlying multiple sclerosis. *Rom J Neurol* 2010; 9: 68-73.
- [32] Bajkó Z, **Bălașa R**, Petruțiu S, Toma L, Russu S, Pascu I. Mobile carotid artery thrombus. *Rom J Neurol* 2009; 8: 184-186.
- [33] Ștefanache F, **Bălașa R**, Boieru G, Cârciumaru N, Dutoiu H, Georgescu C, Mărginean I, Perju-Dumbravă L, Zaharia C. Monitorizarea eficacității și siguranței Bilobil Forte la pacienții cu disfuncții cognitive severe. *Rom J Neurol* 2008; 7: 88-89.
- [34] **Bălașa R**, Mihuț E, Lukacs E. Tulburările cognitive în scleroza multiplă. *Rev Med Farm* 2008; 54: 136-145.
- [35] **Bălașa R**. Pediatric multiple sclerosis. *Rom J Neurol* 2007; 6: 171-175.

## **VII. Lucrări științifice de specialitate publicate în extenso în reviste cotate B/C**

- [1] **Bălașa R**, Feier C, Dan M, Moțățăianu A, Balaianu M, Chebuț C, Constantin V, Bajkó Z, Pascu I. The prevalence of multiple sclerosis in Mures County, Central Romania. *Rev Rom Neurol* 2007; 6: 80-84.
- [2] **Bălașa R**. Hipotermia controlată în atacul cerebrovascular. *Rev Rom Neurol* 2007; 6: 3-8.
- [3] **Bălașa R**. Scleroza multiplă primar progresivă. *Rev Rom Neurol* 2006; 5: 135-141.
- [4] Pascu I, **Bălașa R**. Moartea creierului. *Brit Med J-Ed Română* 2004; 11: 90-95.
- [5] Pascu I, **Bălașa R**. Principii de tratament ale epilepsiei la adult. *Rev Rom Neurol* 2003; 2: 6-8.
- [6] **Bălașa R**. Potențialele evocate în scleroza multiplă și nevrita optică. *Rev Med Farm* 2001; 47: 131-136.
- [7] **Bălașa R**. Nevrita optică și relația acesteia cu scleroza multiplă. *Rev Med Farm* 2001; 47: 1-7.
- [8] Corfariu O, Chioreanu M, **Bălașa R**, Dicu S. Explorări de electroneurofiziologie clinică la bolnavul critic în unitățile de terapie intensivă. *J Soc Rom ATI* 2001; 8: 134-137.
- [9] **Bălașa R**. Visual evoked potentials and magnetic resonance imaging in multiple sclerosis patients with clinical and subclinical optic neuritis. *Rev Med Farm* 2000; 46: 245-247.
- [10] **Bălașa R**. Imagistica prin rezonanță magnetică în scleroza multiplă și nevrita optică. *Rev Med Farm* 2000; 46: 9-20.
- [11] Moldovan E, **Bălașa R**. Modificări microscopice în timus la bolnavii cu myasthenia gravis. *Rev Med Farm* 1999; 45: 218-222.
- [12] Pascu I, Pascu R, **Bălașa R**. Borrelioza (boala Lyme). *Rev Med Farm* 1998; 44: 252-260.

**VIII. Lucrări științifice de specialitate prezentate la Congrese Naționale și Internaționale, cu rezumate/postere publicate în reviste cotate ISI.**

❖ *Annual meeting of the American-Association-of-Neuromuscular-and-Electrodiagnostic-Medicine (AANEM) ; Austin, Texas, 16-19 october 2019.*

1. Elsa Mondou, Rodica Balasa, Jan L. De Bleecker, Philip Van Damme, Emmeline Lagrange, Jeannine Heckmann, Michael Nicolle, Crisandra Vilciu, Vera Bril, Rhonda Griffin, Junliang Chen, Beatriz Garcia, Sandra Camprubi, Jaume Ayguasanosa. Efficacy and safety of immunoglobulin caprylate/chromatography purified (Igiv-c) in patients with myasthenia gravis exacerbations: a multicenter, prospective, open-label, noncontrolled clinical trial. *Muscle & Nerve*;60(2019):S47-S47. IF : **2.39**.

❖ *35th Congress of the European Committee for Treatment and Research in multiple sclerosis and 24th Annual conference of Rehabilitation in MS, 11-13 september, Stockolm, Sweden, 2019.*

1. **Balasa R**, Manu D, Romaniuc A, Dobreanu M, Experimental model of isolation, cultivation and exposure to cladribine of T lymphocytes from multiple sclerosis patients: a step towards personalized treatment. *Multiple Sclerosis Journal* 2019 ;25 (SI-2) :210-211. EP P477. IF : **5.64**.

❖ *The 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, 29 june – 02 July 2019.*

1. Karelis G, Balasa R, DeBleecker JL, Van Damme P, Lagrange E, Heckmann J, Nicolle M, Vilciu C, Bril V, Mondou E, Griffin R, Chen J, Henriquez W, Garcia B, Camprubil S, Ayguasanosa J. Efficacy and safety of IGIV-C in patients with myasthenia gravis exacerbations : a multicenter prospective, open label, non-controlled clinical trial. *European Journal of Neurology*. 2019 ;26(1) :689-689, EPO2239. IF : **4.38**.

❖ *The 3rd congress of the European-Academy-of-Neurology, Amsterdam, Netherlands, june 2017.*

1. **Balasa R**, Hutanu A, Pure D, Voidazan S, Barcutean L, Maier MS. The expression of matrix metalloproteinase peripheral profile in multiple sclerosis patients treated with natalizumab : possible additional mechanisms of natalizumab action. *European Journal of Neurology* 2017 ;24 :190-190, EP1134, IF:**4.62**.

❖ *32<sup>nd</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis ; 21<sup>st</sup> Annual Conference of Rehabilitation in MS, London, United Kingdom, 14-17 September, 2016.*

1. **Balasa R**, Bajkó Z, Hutanu A, Voidazan S, Maier SM. *Natalizumab treatment modifies peripheral cytokine profile in multiple sclerosis patients*. ECTRIMS Online Library, Eposter P1165.

2. Maier S, **Balasa R**, Bajkó Z, Barcutean L, Voidazan S, Motataianu A, Stirbu N. *The risk factors for suicidal ideation in a Romanian cohort of multiple sclerosis patients*. ECTRIMS Online Library, Eposter P1468.

❖ *2<sup>nd</sup> Congress of European Academy of Neurology, Copenhagen, Denmark, 28-31 May, 2016.*

1. Maier S, Bajkó Z, Moțățianu A, Bărcuțean L, Voidăzan S, **Bălașa R**. *The effects of smoking on clinical evolution of multiple sclerosis patients treated with first line DMTs.* Eur J Neurol 2016; 23 (Suppl 1): 332. **IF: 3.956.**

❖ *1<sup>st</sup> Congress of the European Academy of Neurology, Berlin, Germany, 20-23 June, 2015.*

1. Maier S, Bajkó Z, Huțanu A, **Bălașa R**. *The correlation between IL-17 serum levels and clinical evolution and MRI lesion load in multiple sclerosis patients treated with interferon beta 1a i.m.* Eur J Neurol 2015 ; 22 (Suppl 1) : 837. **IF : 4.060.**

❖ *1<sup>st</sup> Congress of Romanian Association of Laboratory Medicine with International Participants, Sighișoara, România, 20-23<sup>rd</sup> May, 2015.*

1. Mărginean A, Bănescu C, Șular FL, **Bălașa R**, Maier S, Ispas M, Țăruși M, Dobreanu M. *Rezistența la terapia cu antiagregante plachetare – o problemă reală în România.* Rev Rom Med Lab 2015; 23 (Supl): S85. **IF: 0.171.**

❖ *Al XXII Congres Național al Societății Române de Endocrinologie, Târgu Mureș, Romania, 2-4 Octombrie, 2014.*

1. Huțu S, Cota A, Căpraru O-A, **Bălașa R**, Pașcanu I. *Hypokaliemic periodic paralysis in a caucasian man revealing Basedow-Graves disease.* Acta Endocrinol (Buc) 2014; 10 (Suppl 2): 225-226. **IF: 0.210.**

❖ *EFNS-ENS Joint Congress of European Neurology, Istanbul, Turkey, 31 May-3 June, 2014.*

1. Rusu S, **Bălașa R**, Maier S, Moțățianu A, Costache O, Bajkó Z. *Bilateral carotid occlusion.* Eur J Neurol 2014; 21 (Suppl 1): P4030. **IF: 4.162.**

❖ *Twenty-second Meeting of the European Neurological Society, Prague, Csech Republic, 9 – 12 June, 2012.*

1. Moțățianu A, **Bălașa R**, Bajkó Z. *Relationship between severity of cardiovascular autonomic neuropathy and diabetic complications of type 2 diabetes mellitus.* J Neurol 2012; 259 (Suppl 1): P523. **IF: 3.841.**

❖ *The 16<sup>th</sup> Congress of the EFNS, Stockholm, Sweden, 8-11 September, 2012.*

1. Chebuț C, **Bălașa R**, Bajkó Z, Mocan S. *The challenges in establishing a positive diagnosis of seronegative Wegener's Granulomatosis with unusual clinical presentation: a case report.* Eur J Neurol 2012; 19 (Suppl 1): P1894. **IF: 4.162.**

❖ *The 15<sup>th</sup> Congress of the EFNS, Budapest, Hungary, 10-13 September, 2011.*

1. **Bălașa R**, Huțanu A, Bajkó Z, Feier C. *Serum IL-17A titre in MS patients treated with IFN-β.* Eur J Neurol 2011 ; 18 (Suppl 2): P1550, ISSN 1468-1331, **IF: 3.692.**

2. Feier C, **Bălașa R**, Bălașa A, Treabă A. *Multiple spinal epidural hydatid cysts: a case presentation.* Eur J Neurol 2011; 18 (Suppl 2): P2380. **IF: 3.692.**

❖ *The 6<sup>th</sup> World Stroke Congress, Vienna, Austria, 24-27 September, 2008.*

1. Toma L, Szekeres C, **Bălașa R**. *Brainstem syndrome, the worst prognosis for intracerebral haemorrhage*. Int J Stroke 2008; 3 (Suppl 1) PO01-403. **IF: 2.000.**
2. Bajkó Z, Szatmari S, **Bălașa R**, Szekeres CS, Fekete K, Csiba L, Bereczki D. *Gender differences in blood pressure indices and short term stroke outcome*. Int J Stroke 2008; 3 (Suppl 1): PO02-525. **IF: 2.000.**

❖ *The 12th Congress of the EFNS, Madrid, Spain, 23 – 26 August, 2008.*

1. Bajkó Z, Szatmari S, **Bălașa R**, Szekeres CS, Fekete K, Csiba L, Bereczki D. *The effect of admission blood pressure indices on short-term stroke outcome*. Eur J Neurol 2008; 15 (Suppl 3): P1110, ISSN 1468-1331, **IF: 2.732.**
2. Bârsan A, **Bălașa R**, Buruian M, Bajkó Z, Incze T. *MRI validated Van der Knaap disease in a 38 year-old woman*. Eur J Neurol 2008; 15 (Suppl 3): P2299, ISSN 1468-1331, **IF: 2.732.**

❖ *Seventeenth Meeting of the European Neurological Society, Rhodes, Greece, 16-20 June, 2007.*

1. Chebuț O, **Bălașa R**, Dan M. *The importance of an early initiation in the immunomodulatory therapy for multiple sclerosis*. J Neurol 2007; 254 (Suppl 3): P413, ISSN 0340-5354, **IF: 2.477.**

❖ *The 11th Congress of the EFNS, Brussels, Belgium, 25-28 August, 2007.*

1. Chebuț C, **Bălașa R**, Moldovan E, Dan M. *Thymic abnormalities in myasthenia gravis*. Eur J Neurol 2007; 14 (Suppl 1): P2383, ISSN: 1468-1331, **IF: 2.580.**

❖ *The XI International Congress of EMG an Clinical Neurophysiology, Prague, Czech Republic, September 7-11, 1999.*

1. **Bălașa R**, Pascu I. *Visual evoked potentials modifications in multiple sclerosis patients*. Clin Neurophysiol 1999; 110: S112, ISSN: 1388-2457.

